Correlation of PSMA PET and Post-therapy SPECT Imaging Metrics with Absorbed Doses for 177Lu-PSMA-617 Therapy

被引：0
|
作者：
Meyer, Catherine [1 ]
Yilmaz, Burcak [1 ]
Winters, Celeste [1 ]
Mench, Anna [1 ]
Mallak, Nadine [1 ]
Mittra, Erik [1 ]
机构：
[1] OHSU, Portland, OR USA
来源：
JOURNAL OF NUCLEAR MEDICINE | 2024年 / 65卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
242420
引用
收藏
页数：3
相关论文
共 50 条
  • [21] 177Lu-PSMA-617 vs Cabazitaxel in MCRPC
    不详
    JOURNAL OF NUCLEAR MEDICINE, 2021, 62 (04) : 13N - 13N
  • [22] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Kambiz Rahbar
    Hojjat Ahmadzadehfar
    Martin Boegemann
    European Journal of Nuclear Medicine and Molecular Imaging, 2018, 45 : 513 - 514
  • [23] Experimental 177Lu-PSMA-617 radioligand therapy in a patient with extended metastasized leiomyosarcoma
    Jueptner, Michael
    Marx, Marlies
    Zuhayra, Maaz
    Luetzen, Ulf
    NUKLEARMEDIZIN-NUCLEAR MEDICINE, 2019, 58 (04): : 328 - 330
  • [24] 177Lu-PSMA-617 radioligand therapy in mCRPC: ready for phase III trial?
    Rahbar, Kambiz
    Ahmadzadehfar, Hojjat
    Boegemann, Martin
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2018, 45 (03) : 513 - 514
  • [25] 177Lu-PSMA-617 therapy in Chemotherapy Naive patients: A single center experience
    Kulkarni, Raksha
    Abdelrahman, Ahmed
    Novello, Matteo
    Cengiz, Turgut Bora
    Akinlusi, Rahman
    Bander, Ilda
    Patel, Vaibhav
    Wise, David
    Ghesani, Munir
    Ghesani, Nasrin
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [26] 177Lu-PSMA-617 Therapy in a Patient on Haemodialysis with End Stage Renal Failure
    MacFarlane, L.
    Eifer, M.
    Saghebi, J.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S248 - S248
  • [27] Influence of androgen receptor signaling inhibitors on absorbed doses in mCRPC patients undergoing 177Lu-PSMA-617 therapy: First dosimetry results
    Zahner, Josef
    Delker, Astrid
    Holzgreve, Adrien
    Unterrainer, Marcus
    Ells, Zachary
    Tiling, Maximilian
    Sheikh, Gabriel
    Zacherl, Mathias
    Berg, Elena
    Aydogdu, Can
    Kunte, Sophie Carina
    Bartenstein, Peter
    Boening, Guido
    Calais, Jeremie
    Stief, Christian
    Casuscelli, Jozefina
    Unterrainer, Lena
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [28] First Experience With 177Lu-PSMA-617 Therapy for Advanced Prostate Cancer in the Netherlands
    van Kalmthout, Ludwike
    Braat, Arthur
    Lam, Marnix
    van Leeuwaarde, Rachel
    Krijger, Gerard
    Ververs, Tessa
    Mehra, Niven
    Bins, Adriaan
    Hunting, Jarmo
    de Keizer, Bart
    CLINICAL NUCLEAR MEDICINE, 2019, 44 (06) : 446 - 451
  • [29] Management of Dry Mouth Toxicity Following 177Lu-PSMA-617 Radioligand Therapy
    Pepin, Abigail
    Kiess, Ana
    Lukens, J. Nicholas
    Mulugeta, Philipose
    Taunk, Neil K.
    PRACTICAL RADIATION ONCOLOGY, 2025, 15 (01) : 14 - 18
  • [30] Prognostic value of post-therapy SPECT/CT imaging in patients undergoing [177Lu]Lu-PSMA-617 radioligand therapy: results from 3 clinical trials
    Karri, Raghava
    Buteau, James
    Eifer, Michal
    Bollampally, Neeraja
    Bressel, Mathias
    Sandhu, Shahneen
    Hofman, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
12345